Literature DB >> 18753723

Serum interleukin-6 levels, not genotype, correlate with coronary plaque complexity.

Li-Tang Kuo1, Ning-I Yang, Wen-Jin Cherng, Subodh Verma, Ming-Jui Hung, Shih-Yi Wang, Min-hui Liu, Shu-yi Chen, Chao-Hung Wang.   

Abstract

An increased serum interleukin-6 (IL-6) level is associated with an increased risk of cardiovascular events in healthy subjects. However, it is unknown whether the level of serum IL-6 or genetic IL-6 polymorphism is correlated with the complexity of coronary plaque in patients with stable coronary artery disease (CAD). Patients with stable CAD (n = 135) were divided into 3 groups: insignificant coronary plaque (n = 77), simple coronary plaque (n = 15), and complex coronary plaque (n = 43). IL-6-174G > C polymorphism and serum levels of IL-6 and C-reactive protein (CRP) were investigated. No significant difference in the distribution of IL-6 genotypes was found among the groups. The presence of complex coronary plaque was associated with higher serum concentrations of IL-6 (P = 0.026) and CRP (P < 0.0001). To predict the presence of complex lesions, IL-6 > 5.8 ng/L and CRP > 2.6 mg/L had sensitivities of 86% and 74%, and specificities of 61% and 62%, respectively. By multivariate analysis, IL-6 > 5.8 ng/L and CRP > 2.6 mg/L were independently related to the presence of complex coronary plaque (P = 0.0002 and 0.004, respectively). IL-6 > 5.8 ng/L and CRP > 2.6 mg/L were associated with a 4.5-fold increase in the odds of having complex coronary plaque (P < 0.005). A simple measurement of the serum IL-6 level in patients with CAD can potentially identify subjects with complex coronary lesions and provide the option of aggressive medical strategies in a clinical setting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753723     DOI: 10.1536/ihj.49.391

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  7 in total

1.  The endothelial dysfunction in patients with type 2 diabetes mellitus is associated with IL-6 gene promoter polymorphism in Chinese population.

Authors:  Xianfeng Zhang; Lizhen Ma; Fengying Peng; Yin Wu; Yu Chen; Linying Yu; Zhikai Lei; Chu Zhang
Journal:  Endocrine       Date:  2011-03-18       Impact factor: 3.633

2.  Association of serum omentin-1 levels with coronary artery disease.

Authors:  Xia Zhong; Hai-yang Zhang; Hui Tan; Yi Zhou; Fu-li Liu; Fu-qin Chen; De-ya Shang
Journal:  Acta Pharmacol Sin       Date:  2011-05-23       Impact factor: 6.150

3.  Interleukin-6 and E-selectin in acute coronary syndromes and stable angina pectoris. A comparative study.

Authors:  N Sarrafzadegan; M Sadeghi; F Ghaffarpasand; A Alisaeidi; H Sanei; H Zakeri; T Rastegar; A Amiri; M Dehghankhalili
Journal:  Herz       Date:  2012-07-07       Impact factor: 1.443

4.  Low-density lipoprotein apheresis as a treatment option for hyperlipidemia.

Authors:  Puja K Mehta; Jefferson Baer; Christine Nell; Laurence S Sperling
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

5.  Genetic Variation in NFKB1 and NFKBIA and Susceptibility to Coronary Artery Disease in a Chinese Uygur Population.

Authors:  Hong-Mei Lai; Xiao-Mei Li; Yi-Ning Yang; Yi-Tong Ma; Rui Xu; Shuo Pan; Hui Zhai; Fen Liu; Bang-Dang Chen; Qian Zhao
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

6.  Expression of adipocytokines in heart fat depots depending on the degree of coronary artery atherosclerosis in patients with coronary artery disease.

Authors:  Olga V Gruzdeva; Ekaterina V Belik; Yulia A Dyleva; Daria A Borodkina; Maxim Yu Sinitsky; Danil Yu Naumov; Evgeniya E Bychkova; Elena V Fanaskova; Elena I Palicheva; Anastasia A Kuzmina; Viktoriya N Karetnikova; Olga L Barbarash
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

7.  Association of interleukin 6 -174 G/C polymorphism with coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis.

Authors:  Himanshu Rai; Roisin Colleran; Salvatore Cassese; Michael Joner; Adnan Kastrati; Robert A Byrne
Journal:  Inflamm Res       Date:  2021-09-30       Impact factor: 4.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.